Correlation Between Vaccinex and Bio Path
Can any of the company-specific risk be diversified away by investing in both Vaccinex and Bio Path at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vaccinex and Bio Path into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Vaccinex and Bio Path Holdings, you can compare the effects of market volatilities on Vaccinex and Bio Path and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vaccinex with a short position of Bio Path. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vaccinex and Bio Path.
Diversification Opportunities for Vaccinex and Bio Path
Good diversification
The 3 months correlation between Vaccinex and Bio is -0.04. Overlapping area represents the amount of risk that can be diversified away by holding Vaccinex and Bio Path Holdings in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Bio Path Holdings and Vaccinex is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vaccinex are associated (or correlated) with Bio Path. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Bio Path Holdings has no effect on the direction of Vaccinex i.e., Vaccinex and Bio Path go up and down completely randomly.
Pair Corralation between Vaccinex and Bio Path
Given the investment horizon of 90 days Vaccinex is expected to generate 1.77 times more return on investment than Bio Path. However, Vaccinex is 1.77 times more volatile than Bio Path Holdings. It trades about 0.04 of its potential returns per unit of risk. Bio Path Holdings is currently generating about -0.25 per unit of risk. If you would invest 374.00 in Vaccinex on August 29, 2024 and sell it today you would lose (5.00) from holding Vaccinex or give up 1.34% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Vaccinex vs. Bio Path Holdings
Performance |
| Timeline |
| Vaccinex |
| Bio Path Holdings |
Vaccinex and Bio Path Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Vaccinex and Bio Path
The main advantage of trading using opposite Vaccinex and Bio Path positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vaccinex position performs unexpectedly, Bio Path can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bio Path will offset losses from the drop in Bio Path's long position.| Vaccinex vs. Eliem Therapeutics | Vaccinex vs. Scpharmaceuticals | Vaccinex vs. Milestone Pharmaceuticals | Vaccinex vs. Seres Therapeutics |
| Bio Path vs. Capricor Therapeutics | Bio Path vs. NextCure | Bio Path vs. Pulmatrix | Bio Path vs. Crinetics Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Complementary Tools
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |